TrialInflammatory bowel diseases2026

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.

Anita Afzali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.